Fig. 2From: In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell linePlot of experimental Pic50 of both the model building and the external validation set against their residualsBack to article page